immunitybio - IBRX
IBRX
Close Chg Chg %
2.20 0.04 1.82%
Closed Market
2.24
+0.04 (1.82%)
Volume: 7.67M
Last Updated:
Jan 8, 2026, 4:00 PM EDT
Company Overview: immunitybio - IBRX
IBRX Key Data
| Open $2.16 | Day Range 2.14 - 2.28 |
| 52 Week Range 1.83 - 4.27 | Market Cap $2.11B |
| Shares Outstanding 984.97M | Public Float 330.75M |
| Beta -0.10 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.41 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 12.60M |
IBRX Performance
| 1 Week | 13.13% | ||
| 1 Month | -5.08% | ||
| 3 Months | -5.08% | ||
| 1 Year | -7.44% | ||
| 5 Years | -84.30% |
IBRX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About immunitybio - IBRX
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
IBRX At a Glance
ImmunityBio, Inc.
3530 John Hopkins Court
San Diego, California 92121
| Phone | 1-844-696-5235 | Revenue | 14.75M | |
| Industry | Pharmaceuticals: Major | Net Income | -413,564,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 2,270.579% | |
| Fiscal Year-end | 12 / 2025 | Employees | 680 | |
| View SEC Filings |
IBRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 121.61 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.452 |
| Enterprise Value to Sales | 165.081 |
| Total Debt to Enterprise Value | 0.324 |
IBRX Efficiency
| Revenue/Employee | 21,683.824 |
| Income Per Employee | -608,182.353 |
| Receivables Turnover | 5.558 |
| Total Asset Turnover | 0.033 |
IBRX Liquidity
| Current Ratio | 3.36 |
| Quick Ratio | 3.209 |
| Cash Ratio | 2.727 |
IBRX Profitability
| Gross Margin | -19.051 |
| Operating Margin | -2,334.229 |
| Pretax Margin | -2,805.324 |
| Net Margin | -2,804.774 |
| Return on Assets | -93.21 |
| Return on Equity | N/A |
| Return on Total Capital | -137.525 |
| Return on Invested Capital | -142.139 |
IBRX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 262.642 |
| Total Debt to Total Assets | 206.255 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 259.745 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Immunitybio - IBRX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 934.00K | 240.00K | 622.00K | 14.74M | |
Sales Growth
| +741.44% | -74.30% | +159.17% | +2,270.58% | |
Cost of Goods Sold (COGS) incl D&A
| - | 24.19M | 18.51M | 17.55M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 19.12M | 24.19M | 18.51M | 17.55M | |
Depreciation
| 19.12M | 22.29M | 16.51M | 15.55M | |
Amortization of Intangibles
| - | 1.90M | 2.00M | 2.00M | |
COGS Growth
| - | - | -23.48% | -5.18% | - |
Gross Income
| - | (23.95M) | (17.89M) | (2.81M) | |
Gross Income Growth
| - | - | +25.31% | +84.30% | - |
Gross Profit Margin
| - | -9,980.00% | -2,876.21% | -19.05% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 312.09M | 326.67M | 343.47M | 341.37M | |
Research & Development
| 195.96M | 229.89M | 213.85M | 188.14M | |
Other SG&A
| 116.13M | 96.78M | 129.62M | 153.23M | |
SGA Growth
| +277.88% | +4.67% | +5.15% | -0.61% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 4.62M | (8.59M) | 86.28M | (76.27M) | |
EBIT after Unusual Expense
| (334.89M) | (342.03M) | (447.64M) | (267.91M) | |
Non Operating Income/Expense
| 393.00K | (10.26M) | (7.05M) | 8.59M | |
Non-Operating Interest Income
| 836.00K | 2.71M | 2.71M | 8.65M | |
Equity in Earnings of Affiliates
| - | - | (12.11M) | (7.55M) | - |
Interest Expense
| 15.34M | 65.00M | 129.20M | 154.33M | |
Interest Expense Growth
| +1,606.01% | +323.82% | +98.76% | +19.45% | |
Gross Interest Expense
| 15.34M | 65.00M | 129.20M | 154.33M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (349.84M) | (417.29M) | (583.89M) | (413.64M) | |
Pretax Income Growth
| -278.70% | -19.28% | -39.93% | +29.16% | |
Pretax Margin
| -37,456.00% | -173,869.17% | -93,873.31% | -2,805.32% | |
Income Tax
| - | 9.00K | 34.00K | (40.00K) | |
Income Tax - Current - Domestic
| - | 9.00K | 38.00K | (26.00K) | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | (4.00K) | (14.00K) | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | (12.11M) | (7.55M) | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (349.85M) | (417.32M) | (583.85M) | (413.64M) | |
Minority Interest Expense
| (3.06M) | (753.00K) | (656.00K) | (81.00K) | |
Net Income
| (346.79M) | (416.57M) | (583.20M) | (413.56M) | |
Net Income Growth
| -275.38% | -20.12% | -40.00% | +29.09% | |
Net Margin Growth
| -37,129.55% | -173,569.58% | -93,761.41% | -2,804.77% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (346.79M) | (416.57M) | (583.20M) | (413.56M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (346.79M) | (416.57M) | (583.20M) | (413.56M) | |
EPS (Basic)
| -0.891 | -1.0417 | -1.1466 | -0.5931 | |
EPS (Basic) Growth
| +0.13% | -16.91% | -10.07% | +48.27% | |
Basic Shares Outstanding
| 389.23M | 399.90M | 508.64M | 697.31M | |
EPS (Diluted)
| -0.891 | -1.0417 | -1.1466 | -0.6189 | |
EPS (Diluted) Growth
| +0.13% | -16.91% | -10.07% | +46.02% | |
Diluted Shares Outstanding
| 389.23M | 399.90M | 508.64M | 700.44M | |
EBITDA
| (311.16M) | (326.43M) | (342.85M) | (326.63M) | |
EBITDA Growth
| -277.26% | -4.91% | -5.03% | +4.73% | |
EBITDA Margin
| -33,314.56% | -136,010.42% | -55,120.90% | -2,215.18% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 10.20 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.076 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.322 | |
| Last Quarter’s Earnings | -0.09 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.452 | Next Fiscal Year Estimate | -0.023 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 5 | 3 |
| Mean Estimate | -0.08 | -0.08 | -0.32 | -0.02 |
| High Estimates | -0.07 | -0.06 | -0.24 | 0.16 |
| Low Estimate | -0.09 | -0.10 | -0.44 | -0.22 |
| Coefficient of Variance | -15.71 | -25.37 | -27.29 | -815.80 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Immunitybio - IBRX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Immunitybio - IBRX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 7, 2026 | Richard Adcock CEO & President; Director | 368,901 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | Richard Adcock CEO & President; Director | 351,391 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.98 per share | 695,754.18 |
| Jan 7, 2026 | Richard Adcock CEO & President; Director | 51,731 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | David Sachs Chief Financial Officer | 256,017 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 7, 2026 | David Sachs Chief Financial Officer | 240,582 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.98 per share | 476,352.36 |
| Jan 7, 2026 | David Sachs Chief Financial Officer | 45,602 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Patrick Soon-Shiong See remarks; Director | 29,588,261 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Patrick Soon-Shiong See remarks; Director | 29,546,190 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.42 per share | 101,047,969.80 |
| Feb 26, 2025 | Patrick Soon-Shiong See remarks; Director | 228,658 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Barry J. Simon Director | 3,249,024 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Barry J. Simon Director | 3,243,571 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.42 per share | 11,093,012.82 |
| Feb 26, 2025 | Barry J. Simon Director | 30,488 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Regan J. Lauer Chief Accounting Officer | 111,927 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | Regan J. Lauer Chief Accounting Officer | 110,258 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.42 per share | 377,082.36 |
| Feb 26, 2025 | Regan J. Lauer Chief Accounting Officer | 8,130 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |